Development of a Selective and High Affinity Radioligand, [3H]VU6013720, for the M4Muscarinic Receptor

The PET tracer [ 11 C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer’s disease

(2022) Wenping Li et al.   Science Translational Medicine

Structure–activity relationship of pyrazol-4-yl-pyridine derivatives and identification of a radiofluorinated probe for imaging the muscarinic acetylcholine receptor M4

(2022) Ahmed Haider et al.   Acta Pharmaceutica Sinica B

Targeting muscarinic receptors to treat schizophrenia

(2021) Daniel J. Foster et al.   BEHAVIOURAL BRAIN RESEARCH

Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist

(2021) Matthew Spock et al.   ACS Medicinal Chemistry Letters

Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M4 muscarinic acetylcholine receptor

(2021) Aaron M. Bender et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of [11C]MK-6884: A Positron Emission Tomography (PET) Imaging Agent for the Study of M4Muscarinic Receptor Positive Allosteric Modulators (PAMs) in Neurodegenerative Diseases

(2020) Ling Tong et al.   JOURNAL OF MEDICINAL CHEMISTRY

Synthesis and preliminary evaluation of 4-hydroxy-6-(3-[11C]methoxyphenethyl)pyridazin-3(2H)-one, a 11C-labeled -amino acid oxidase (DAAO) inhibitor for PET imaging

(2020) Xiaoyun Deng et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia

(2020) Brian Dean et al.   PSYCHIATRY RESEARCH

Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders

(2019) Mark S. Moehle et al.   MOVEMENT DISORDERS

Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders

(2019) Sean P. Moran et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Differential Pharmacology and Binding of mGlu2Receptor Allosteric Modulators

(2018) Daniel E. O’Brien et al.   MOLECULAR PHARMACOLOGY

Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases

(2018) Christian C. Felder et al.   NEUROPHARMACOLOGY

Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease

(2018) E.P. Lebois et al.   NEUROPHARMACOLOGY

Synthesis and Preliminary Evaluation of 11 C-Labeled VU0467485/AZ13713945 and Its Analogues for Imaging Muscarinic Acetylcholine Receptor Subtype 4

(2018) Xiaoyun Deng et al.   ChemMedChem

Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M 4 Muscarinic Receptor

(2017) Mark S. Moehle et al.   NEURON

Antipsychotic-like Effects of M 4 Positive Allosteric Modulators Are Mediated by CB 2 Receptor-Dependent Inhibition of Dopamine Release

(2016) Daniel J. Foster et al.   NEURON

Allosteric activation of M4muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice

(2015) Tristano Pancani et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Selective Activation of M4 Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents

(2014) Michael Bubser et al.   ACS Chemical Neuroscience

A Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors Plays a Critical Role in Modulating Dopamine-Dependent Behaviors

(2010) J. Jeon et al.   JOURNAL OF NEUROSCIENCE

Treatment strategies for dystonia

(2009) Leslie J Cloud et al.   EXPERT OPINION ON PHARMACOTHERAPY